Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.

Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S.

J Thromb Haemost. 2019 May 24. doi: 10.1111/jth.14491. [Epub ahead of print]

PMID:
31124272
2.

Higher macrophage superoxide anion production in coronary artery disease (CAD) patients with Type D personality.

Zuccarella-Hackl C, von Känel R, Thomas L, Kuebler P, Schmid JP, Mattle HP, Mono ML, Rieben R, Wiest R, Wirtz PH.

Psychoneuroendocrinology. 2016 Jun;68:186-93. doi: 10.1016/j.psyneuen.2016.02.031. Epub 2016 Mar 2.

PMID:
26994482
3.

Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.

Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):184-8. doi: 10.1097/QAI.0000000000000923.

4.

Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.

Ferenc M, Buettner HJ, Gick M, Comberg T, Rothe J, Khoury F, Valina C, Toma A, Kuebler P, Riede F, Neumann FJ.

Clin Res Cardiol. 2016 Mar;105(3):230-8. doi: 10.1007/s00392-015-0911-7. Epub 2015 Sep 2.

PMID:
26329585
5.

Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.

Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF.

J Infect Dis. 2016 Feb 15;213(4):569-73. doi: 10.1093/infdis/jiv425. Epub 2015 Aug 26.

6.

Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8379-84. doi: 10.1073/pnas.1501443112. Epub 2015 Jun 22.

7.

Antiviral gene expression in psoriasis.

Raposo RA, Gupta R, Abdel-Mohsen M, Dimon M, Debbaneh M, Jiang W, York VA, Leadabrand KS, Brown G, Malakouti M, Arron S, Kuebler PJ, Wu JJ, Pillai SK, Nixon DF, Liao W.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1951-7. doi: 10.1111/jdv.13091. Epub 2015 Mar 23.

8.

Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.

Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, Tuomi L, Ehrlich JS, Rubio RG, Campochiaro PA.

Ophthalmology. 2014 Nov;121(11):2237-46. doi: 10.1016/j.ophtha.2014.05.012. Epub 2014 Jul 4.

PMID:
25001159
9.

Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals.

Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, Liao W, Pillai SK, Nixon DF.

J Leukoc Biol. 2013 Nov;94(5):1051-9. doi: 10.1189/jlb.0313150. Epub 2013 Aug 8.

10.

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.

Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A.

Invest Ophthalmol Vis Sci. 2013 Mar 5;54(3):1616-24. doi: 10.1167/iovs.12-10260.

PMID:
23361508
11.

Skewed distribution of natural killer cells in psoriasis skin lesions.

Batista MD, Ho EL, Kuebler PJ, Milush JM, Lanier LL, Kallas EG, York VA, Chang D, Liao W, Unemori P, Leslie KS, Maurer T, Nixon DF.

Exp Dermatol. 2013 Jan;22(1):64-6. doi: 10.1111/exd.12060.

12.

Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease.

Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV, Martin MP, Fernandez Vina MA, McVean G, Wabl M, Leslie KS, Maurer T, Martin JN, Deeks SG, Carrington M, Bowcock AM, Nixon DF, Liao W.

PLoS Genet. 2012 Feb;8(2):e1002514. doi: 10.1371/journal.pgen.1002514. Epub 2012 Feb 16.

13.

Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility.

Lai OY, Chen H, Michaud HA, Hayashi G, Kuebler PJ, Hultman GK, Ariza ME, Williams MV, Batista MD, Nixon DF, Foerster J, Bowcock AM, Liao W.

J Invest Dermatol. 2012 Jul;132(7):1833-40. doi: 10.1038/jid.2012.69. Epub 2012 Mar 22.

14.

Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children.

Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF.

PLoS One. 2012;7(1):e29154. doi: 10.1371/journal.pone.0029154. Epub 2012 Jan 11.

15.

Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents.

Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF.

PLoS One. 2011;6(7):e21135. doi: 10.1371/journal.pone.0021135. Epub 2011 Jul 19.

16.

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.

Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC Jr, Liao XC, Lubach JW, Deese A, Sowell CG, Currie KS, Young WB, Khojasteh SC, Hop CE, Wong H.

Drug Metab Dispos. 2011 Oct;39(10):1840-9. doi: 10.1124/dmd.111.040840. Epub 2011 Jul 8.

PMID:
21742900
17.

Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants.

Holditch SJ, Eriksson EM, Tarosso LF, Kuebler PJ, Kallas EG, Nielsen EK, Wiznia AA, Rosenberg MG, Nixon DF.

Front Immunol. 2012 Jan 11;2:94. doi: 10.3389/fimmu.2011.00094. eCollection 2011.

18.

Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned.

Dao L, Jacobs J, Kuebler P, Bakker B, Lippe B.

Growth Horm IGF Res. 2010 Oct;20(5):367-71. doi: 10.1016/j.ghir.2010.07.002. Epub 2010 Aug 13.

PMID:
20708421
19.

Race/ethnicity-based concerns over understanding cancer diagnosis and treatment plan.

Jean-Pierre P, Fiscella K, Griggs J, Joseph JV, Morrow G, Carroll J, Hendren S, Purnell J, Figueroa-Moseley C, Kuebler P, Banerjee TK, Kirshner JJ.

J Natl Med Assoc. 2010 Mar;102(3):184-9.

20.

Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions.

Ferenc M, Gick M, Kienzle RP, Bestehorn HP, Werner KD, Comberg T, Kuebler P, Büttner HJ, Neumann FJ.

Eur Heart J. 2008 Dec;29(23):2859-67. doi: 10.1093/eurheartj/ehn455. Epub 2008 Oct 9.

21.

Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A.

J Clin Oncol. 2008 Dec 10;26(35):5783-8. doi: 10.1200/JCO.2008.17.5950. Epub 2008 Sep 22.

22.

Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma.

Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF.

AIDS Res Hum Retroviruses. 2006 Jan;22(1):52-6.

PMID:
16438646
23.

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R.

J Clin Pharmacol. 2006 Jan;46(1):10-20. Review.

PMID:
16397279
24.

Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A.

N Engl J Med. 2005 May 5;352(18):1851-60.

25.

Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.

Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, Krueger JG, Leonardi C, Miller B, Joshi A.

J Clin Pharmacol. 2005 Mar;45(3):286-98.

PMID:
15703364
26.
27.

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M.

J Clin Invest. 1999 Sep;104(6):R13-8.

28.

Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.

Samlowski WE, Lew D, Kuebler PJ, Kolodziej MA, Medina JE, Mangan KF, Moore DF Jr, Schuller DE, Ensley JF.

Invest New Drugs. 1998-1999;16(3):271-4.

PMID:
10360608
29.

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy.

Nixon DF, Douek D, Kuebler PJ, Jin X, Vesanen M, Bonhoeffer S, Cao Y, Koup RA, Ho DD, Markowitz M.

Immunol Lett. 1999 Mar;66(1-3):219-28.

PMID:
10203058
30.

Cytotoxic T cell induction with ratchet peptide libraries.

Kuebler PJ, Nixon DF.

Vaccine. 1996 Dec;14(17-18):1664-70.

PMID:
9032897
31.

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.

Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D.

Vaccine. 1996 Nov;14(16):1523-30.

PMID:
9014294
32.

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.

Hioe CE, Qiu H, Chend PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, Nixon DF.

Vaccine. 1996 Apr;14(5):412-8.

PMID:
8735553
33.

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al.

J Clin Oncol. 1992 Jul;10(7):1066-73. Erratum in: J Clin Oncol 1993 Feb;11(2):384.

PMID:
1607913

Supplemental Content

Loading ...
Support Center